Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Operations: 2011-2024

Historic Cash from Operations for Agios Pharmaceuticals (AGIO) over the last 14 years, with Dec 2024 value amounting to -$389.8 million.

  • Agios Pharmaceuticals' Cash from Operations fell 4.67% to -$88.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$409.9 million, marking a year-over-year decrease of 24.54%. This contributed to the annual value of -$389.8 million for FY2024, which is 31.68% down from last year.
  • According to the latest figures from FY2024, Agios Pharmaceuticals' Cash from Operations is -$389.8 million, which was down 31.68% from -$296.1 million recorded in FY2023.
  • Agios Pharmaceuticals' Cash from Operations' 5-year high stood at -$290.8 million during FY2020, with a 5-year trough of -$407.3 million in FY2021.
  • Over the past 3 years, Agios Pharmaceuticals' median Cash from Operations value was -$309.5 million (recorded in 2022), while the average stood at -$331.8 million.
  • In the last 5 years, Agios Pharmaceuticals' Cash from Operations plummeted by 40.09% in 2021 and then rose by 24.02% in 2022.
  • Over the past 5 years, Agios Pharmaceuticals' Cash from Operations (Yearly) stood at -$290.8 million in 2020, then plummeted by 40.09% to -$407.3 million in 2021, then grew by 24.02% to -$309.5 million in 2022, then rose by 4.34% to -$296.1 million in 2023, then plummeted by 31.68% to -$389.8 million in 2024.